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During the past six years. we havetreatedeightpatients with cystic fibrosis (CF)
for nephrolithiasis. In seven patients, the stones were comprised of calcium
oxalate. Another six patients had calcium oxalate crystalluria. In our CF popu-
lation of 140 patients, this represents a cumulative incidence ofcalcium oxalate
nephrolithiasis of 5.7 percent and an additional 4.2 percent incidence of crys-
talluria. Experience with these patients is reviewed. Pancreatic insufficiency
was universally associated with nephrolithiasis orcrystalluria. Diabetes and cir-
rhosis were also common. Predisposing factors and potential mechanisms of
stone disease in pancreatic insufficient CF patients are discussed, focusing on
the relationship between fat malabsorption in CF to oxalate metabolism.
INTRODUCTION
Nephrolithiasis is a relatively uncommon clinical problem in pediatric and young
adult patients with an incidence varying regionally in the United States between one in
1000 in the south and one in 7000 in the northern states [1]. Kidney stones are associated
with various pathologic states [2], and their formation is closely related to renal calcium
handling and to the concentration of substances with stone-forming activity in the urine
[3]. Nephrolithiasis causes a classic triad of findings including hematuria, dysuria and
flank pain, but in younger patients the presentation ofnephrolithiasis may be variable [4].
Cystic fibrosis (CF)b is a multi-system genetic disease characterized by abnormal epithe-
lial electrolyte transport. Two ofthe major manifestations ofCF include chronic suppura-
tive lung disease and exocrine pancreatic insufficiency that causes intestinal fat malab-
sorption. The CF-gene product, cystic fibrosis transmembrane conductance regulator
(CFTR) is thought to be a cAMP-dependent chloride channel and is located in many
organs, including the kidney [5].Although its role there is unknown, and no baseline renal
abnormality is defined [6], CF and its therapy is associated with several urinary abnor-
malities. These include hypercalciuria [7, 8], hyperuricosuria [9, 10] and microscopic
nephrocalcinosis [8]. Despite this, reports ofnephrolithiasis in CFpatients are uncommon
[11-13].
We report our experience caring for eight patients with CF and nephrolithiasis at our
CF center overthe past six years. In seven oftheeightpatients, stone analysis revealed the
composition to be calcium oxalate. An additional six patients had calcium oxalate crys-
talluria. The paucity ofinformation about this association led us to review our experience
with CF and calcium oxalate nephrolithiasis focusing on the gastrointestinal manifesta-
tions ofCF, which may predispose these patients to this condition. In addition, we review
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our therapeutic experience with these patients and pose several questions related to future
research.
SUBJECTS AND METHODS
Patients with CF followed at theYale-New Haven Hospital CFCenter are included in
this analysis. The study encompasses asix-yearperiodduring which all oftherenal stones
were diagnosed. The diagnosis ofCF was confirmed by sweat chloride analysis in accor-
dance with the standards of the North American Cystic Fibrosis Foundation. All stones
weredocumentedeitherradiographically, withintravenouspyelogram, ultrasonography or
abdominal radiograph, orby roentgenographic diffraction stone analysis. Crystalluria and
hematuria were diagnosed bymicroscopic examination ofurine specimens. Threepatients
undertook 24-hour urine collections for oxalate while eating a regular diet. Serum
carotene level, an indirect measure offat malabsorption, is available for fourpatients.
The inpatient and outpatient medical record of each patient with calcium oxalate
nephrolithiasis or crystalluria was reviewed retrospectively with regard to age, sex, fami-
ly history, recurrence of stone disease, medications, end-organ complications of CF and
the clinical presence or absence ofpancreatic insufficiency based on growth parameters,
stool characteristics and the need for pancreatic enzyme supplementation.
RESULTS
Patient characteristics are noted in Tables 1-3. The cumulative incidence of
nephrolithiasis at this CF center of approximately'140 patients was 5.7 percent, and an
additional 4.2 percent ofpatients had oxalate crystalluria. Salient features ofthe patients
with stones included an average age of23 years (range 15 to 34 years), a male-to-female
ratio of 0.6:1, a 38 percent incidence ofdiabetes and a 25 percent incidence ofcirrhosis.
Seven ofthe patients with nephrolithiasis presented with renal colic, and the otherpatient
developed pancreatic insufficiency and stone disease after a bout ofacute pancreatitis.
Patients with crystalluria also had an average age of23 years (range five to 33 years),
a male-to-female ratio of 2:1, a 33 percent incidence of diabetes and a 16 percent inci-
dence ofcirrhosis.
All of the patients in both groups were pancreatic insufficient on clinical grounds,
and serum carotene levels were abnonnally low in one patient with nephrolithiasis and in
two patients with crystalluria. Serum carotene level was normal in one additional patient
with crystalluria. One patient with nephrolithiasis and allergic bronchopulmonary
Table 1. Patient characteristics.
Patients with nephrolithiasis (n = 8):
* Age: 15 to 34 years (mean 23 years)
* Three male, five female
* Cirrhosis: 2/8
* Diabetes: 3/8
* Renal colic: 7/8
Patients with crystalluria (n = 6):
* Age: 5 to 33 years (mean 23 years)
* Four male, two female
* Cirrhosis: 1/6
* Diabetes: 2/6
* Hematuria: 4/6
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Table 2. Characteristics ofpatients with nephrolithiasis.
Age Urine Stone Imaging
(yrs) Sex oxalatea analysis study
20 F 56 mg/24 hrs CaOXALATEb IVPC
15 M 53 mg/24 hrs No NAd
19 F NA No IVP
25 F NA CaOXALATE RUSe
20 F NA CaOXALATE NA
34 M NA CaOXALATE NA
179 F 81 mg/24 hrs No KUBf
32h M NA No IVP
a: Normal value for urine oxalate, <40 mg/24 hours; b: CaOXALATE, calcium oxalate; c: IVP,
intravenous pyelogram; d: NA, not available; e: RUS, renal ultrasound;ft KUB, radiograph ofkid-
neys, ureters and bladder; g: Serum carotene level in this patient, 28 ug/dl (0.52 umolll) (normal
value, 70-200 ug/dl, 1.12-3.72 umol/l); h: The etiology of stone disease in this patient is undiag-
nosed.
Table 3. Characteristics ofpatients with crystalluria.
Age Carotenea
(yrs) Sex Hematuria (ug/dl)
29 M + 26
(0.48 umolIl)
33 M + 53
(0.98 umolIl)
24 F + 103
(1.91 umol/l)
5 M NAb
16 F NA
33 M + NA
a: Normal value for serum carotene, 70-200 ugldl, 1.12.-3.72 umol/l; b: NA, not available.
aspergillosis, and one patient with crystalluria and severe reactive airways disease were
treated with chronic, oral corticosteroid therapy. No patient received diuretics, and ofthe
patients with nephrolithiasis and crystalluria, two in each group never received intra-
venous aminoglycosides.
No patient was ill enough to have severe activity limitation, and no bony fractures
occurred in these patients. The spectrum of pulmonary involvement varied. Only one
patient has had recurrent renal colic, and no renal impairment was noted. Family history
ofnephrolithiasis was negative in all cases. Genetic analysis ofthese patients was unavail-
able.
DISCUSSION
This series of patients with CF and calcium oxalate nephrolithiasis or crystalluria
strongly supports evidence ofan association between these two conditions. The universal
association between fat malabsorption due to pancreatic insufficiency and oxalate
nephrolithiasis may provide an important mechanistic clue regarding the pathogenesis of
stone disease in CF. Enteric hyperoxaluria with nephrolithiasis is well described in
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patients with gastrointestinal disorders, and in particular, malabsorption offat [14]. The
mechanism ofenteric hyperoxaluria is well characterized [15-18].
In enteric hyperoxaluria, excess free fatty acids in the gastro-intestinal tract complex
with dietary calcium to form insoluble soaps. This pool of dietary calcium is rendered
unavailable to bind with dietary oxalate. (Calcium oxalate is a highly insoluble salt,
responsible for fecal excretion ofmost dietary oxalate.) Oxalate, which is unbound to cal-
cium complexes with other cations, such as sodium, forms soluble salts that are readily
absorbed. The pool of passively absorbed oxalate is expanded, increasing the filterable
load of oxalate on the nephron. In the proper biochemical milieu, supersaturation of the
urine with calcium and oxalate can occur, followed by crystallization, and possibly stone
formation.
In enteric hyperoxaluria, the degree offat malabsorption has been directly correlated
with oxalate hyperabsorption and hyperoxaluria [15]. In fact, many patients with enteric
hyperoxaluria have recurrent stone disease and acute renal injury has been reported [19].
Pancreatic insufficiency with dietary fat malabsorption commonly occurs in CF despite
pancreatic enzyme replacement therapy. In addition, the disruption ofentero-hepatic cir-
culation ofbile salts is also known to occur in CF [20] and can also lead to oxalate hyper-
absorption by the following mechanism. With decreased absorption of bile salts, the bile
salt load on the colon increases, causing exaggerated mucosal permeability and colonic
hyperabsorption of oxalate [21-23]. We believe that these factors are likely to be closely
related to the oxalate nephrolithiasis and crystalluria demonstrated by these patients.
Treatment of nephrolithiasis has been straightforward, consisting of hydration and
analgesia acutely. Chronic therapy includes dietary avoidance of oxalate, minimizing
steatorrhea with careful adjustment of pancreatic enzyme therapy, with or without the
addition ofantacids to maximize the efficacy of the enzyme dose, and ensuring adequate
hydration. Recurrent renal colic has been problematic for only one patient, but persistent
crystalluria is more common. No evidence ofrenal damage is apparent.
SUMMARY
Based on this series of patients, we report that calcium oxalate nephrolithiasis is a
complication ofCF, with an incidence at this CF center ofover five percent. Diabetes and
cirrhosis were common in our patients, and pancreatic insufficiency with fat malabsorp-
tion was universal. Nephrolithiasis likely results from enteric hyperoxaluria associated
with pancreatic insufficiency, and the effects ofabnormal bile salt metabolism on colonic
oxalate absorption. While these phenomena provide a potential pathophysiologic model,
metabolic studies ofoxalate absorption and metabolism in CF are needed to confirm this
observation as is research exploring the role of CFTR in the kidney. The presentation of
kidney stones in children and young adults with CF should be recognized by the practi-
tioner and nephrolithiasis included in the differential diagnosis of abdominal pain in the
older CF patient.
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